Receptor tyrosine kinase inhibitors in cancer

被引：48

作者：

Ebrahimi, Nasim ^{[1
]}

Fardi, Elmira ^{[2
]}

Ghaderi, Hajarossadat ^{[3
]}

Palizdar, Sahar ^{[4
]}

Khorram, Roya ^{[5
]}

Vafadar, Reza ^{[6
]}

Ghanaatian, Masoud ^{[7
]}

Rezaei-Tazangi, Fatemeh ^{[8
]}

Baziyar, Payam ^{[9
]}

Ahmadi, Amirhossein ^{[10
]}

Hamblin, Michael R. ^{[11
]}

Aref, Amir Reza ^{[12
,13
]}

机构：

[1] Univ Isfahan, Fac Sci & Technol, Dept Cell & Mol Biol & Microbiol, Genet Div, Esfahan, Iran

[2] Islamic Azad Univ Tehran, Med Branch, Tehran, Iran

[3] Pasteur Inst Iran, Lab Regenerat & Med Innovat, Tehran, Iran

[4] Islamic Azad Univ Tehran East Branch, Fac Basic Sci, Div Microbiol, Tehran, Iran

[5] Shiraz Univ Med Sci, Bone & Joint Dis Res Ctr, Dept Orthoped Surg, Shiraz, Iran

[6] Kerman Univ Med Sci, Dept Orthopead Surg, Kerman, Iran

[7] Univ Toulouse III Paul Sabatier, Master Bio Sante Parcours Toulouse Grad Sch Canc A, Toulouse, France

[8] Fasa Univ Med Sci, Sch Med, Dept Anat, Fasa, Iran

[9] Univ Mazandaran, Fac Basic Sci, Dept Mol & Cell Biol, Babolsar, Iran

[10] Persian Gulf Univ, Fac Nano & Bio Sci & Technol, Dept Biol Sci & Technol, Bushehr 75169, Iran

[11] Univ Johannesburg, Fac Hlth Sci, Laser Res Ctr, ZA-2028 Doornfontein, South Africa

[12] Harvard Med Sch, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA

[13] Xsphera Biosci, Translat Med Grp, 6 Tide St, Boston, MA 02210 USA

来源：

CELLULAR AND MOLECULAR LIFE SCIENCES | 2023年 / 80卷 / 04期

基金：

美国国家卫生研究院;

关键词：

Targeted therapy; Immune therapy; RTK inhibitors; Drug resistance; Cancer therapy; RENAL-CELL CARCINOMA; GROWTH-FACTOR; LUNG-CANCER; THERAPEUTIC TARGET; DRUG-RESISTANCE; PHASE-III; HEPATOCELLULAR-CARCINOMA; ONCOGENIC ACTIVATION; ACQUIRED-RESISTANCE; MOLECULAR TARGET;

D O I：

10.1007/s00018-023-04729-4

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Targeted therapy is a new cancer treatment approach, involving drugs that particularly target specific proteins in cancer cells, such as receptor tyrosine kinases (RTKs) which are involved in promoting growth and proliferation, Therefore inhibiting these proteins could impede cancer progression. An understanding of RTKs and the relevant signaling cascades, has enabled the development of many targeted drug therapies employing RTK inhibitors (RTKIs) some of which have entered clinical application. Here we discuss RTK structures, activation mechanisms and functions. Moreover, we cover the potential effects of combination drug therapy (including chemotherapy or immunotherapy agents with one RTKI or multiple RTKIs) especially for drug resistant cancers.

引用

页数：18

共 50 条

[21] Generations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Perils and Progress
Emily H. Castellanos
Leora Horn
Current Treatment Options in Oncology, 2015, 16
[22] Generations of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors: Perils and Progress
Castellanos, Emily H.
Horn, Leora
CURRENT TREATMENT OPTIONS IN ONCOLOGY, 2015, 16 (10)
[23] Small-molecule EGFR tyrosine kinase inhibitors for the treatment of cancer
Lee, Chieh-Chien
Shiao, Hui-Yi
Wang, Wen-Chieh
Hsieh, Hsing-Pang
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2014, 23 (10) : 1333 - 1348
[24] Drug Resistance to EGFR Tyrosine Kinase Inhibitors for Non-small Cell Lung Cancer
Shien, Kazuhiko
Yamamoto, Hiromasa
Soh, Junichi
Miyoshi, Shinichiro
Toyooka, Shinichi
ACTA MEDICA OKAYAMA, 2014, 68 (04) : 191 - 200
[25] Overcoming On-Target Resistance to Tyrosine Kinase Inhibitors in Lung Cancer
Dagogo-Jack, Ibiayi
Engelman, Jeffrey A.
Shaw, Alice T.
ANNUAL REVIEW OF CANCER BIOLOGY, VOL 1, 2017, 1 : 257 - 274
[26] Mechanisms of receptor tyrosine kinase activation in cancer
Du, Zhenfang
Lovly, Christine M.
MOLECULAR CANCER, 2018, 17
[27] Resistance to receptor tyrosine kinase inhibitors in solid tumors: can we improve the cancer fighting strategy by blocking autophagy?
Aveic, Sanja
Tonini, Gian Paolo
CANCER CELL INTERNATIONAL, 2016, 16
[28] Radiotherapy and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors in Renal Cancer
Fiore, Michele
D'Angelillo, Rolando Maria
Greco, Carlo
Fioroni, Iacopo
Ippolito, Edy
Santini, Daniele
Ramella, Sara
CHEMOTHERAPY, 2018, 63 (02) : 83 - 89
[29] Upregulation of Receptor Tyrosine Kinase Activity and Stemness as Resistance Mechanisms to Akt Inhibitors in Breast Cancer
Tsang, Tiffany
He, Qingling
Cohen, Emily B.
Stottrup, Casey
Lien, Evan C.
Zhang, Huiqi
Lau, C. Geoffrey
Chin, Y. Rebecca
CANCERS, 2022, 14 (20)
[30] Targeting Angiogenesis in Colorectal Cancer Tyrosine Kinase Inhibitors
Kircher, Sheetal Mehta
Nimeiri, Halla S.
Benson, Al B., III
CANCER JOURNAL, 2016, 22 (03) : 182 - 189

← 1 2 3 4 5 →